Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Cheryl A. Grandinetti
Observed names:
C A Grandinetti,
Cheryl A. Grandinetti,
Cheryl Grandinetti,
Grandinetti, C.A.
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
National Cancer Institute
ORCID:
0009-0003-5861-8962
Observed ORCID:
0009-0003-5861-8962
OpenAlex ID:
A5064899242
Sorafenib and Sunitinib: Novel Targeted Therapies for Renal Cell Cancer
2007
·
Cheryl A. Grandinetti
, Barry R. Goldspiel
·
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
·
123
Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review
2018
·
Brian Perry
, Will Herrington
, et al.
·
Digital Biomarkers
·
79
PDF
Advancing the Use of Mobile Technologies in Clinical Trials: Recommendations from the Clinical Trials Transformation Initiative
2019
·
Philip Coran
, Jennifer C. Goldsack
, et al.
·
Digital Biomarkers
·
74
New FDA Regulation to Improve Safety Reporting in Clinical Trials
2011
·
Rachel Behrman Sherman
, Janet Woodcock
, et al.
·
New England Journal of Medicine
·
51
PDF
Data Integrity in Global Clinical Trials: Discussions From Joint US Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency Good Clinical Practice Workshop
2020
·
Ni A. Khin
, Gail Francis
, et al.
·
Clinical Pharmacology & Therapeutics
·
38
Clinical Trials: Rethinking How We Ensure Quality
2012
·
Martin J. Landray
, Cheryl Grandinetti
, et al.
·
Drug Information Journal
·
29
Tackling Challenging Data Integrity Topics in 2020: Update on Good Clinical Practice Perspectives from the US FDA and MHRA UK
2021
·
Ni A. Khin
, Cheryl Grandinetti
, et al.
·
Clinical Pharmacology & Therapeutics
·
21
Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an Investigational New Drug Application
2013
·
Patrick Archdeacon
, Cheryl Grandinetti
, et al.
·
Therapeutic Innovation & Regulatory Science
·
17
PDF
Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration–National Institutes of Health Collaboration
2025
·
Donna R. Rivera
, Tracy L. Cutler
, et al.
·
JAMA Network Open
·
10
PDF
Keeping the End in Mind: Reviewing U.S. FDA Inspections of Submissions including Real-World Data
2025
·
Cheryl Grandinetti
, Donna R. Rivera
, et al.
·
Therapeutic Innovation & Regulatory Science
·
9
PDF
Evolving Standards: Good Clinical Practice Insights from US FDA , MHRA UK , and Health Canada
2025
·
Cheryl Grandinetti
, Mandy Budwal‐Jagait
, et al.
·
Clinical Pharmacology & Therapeutics
·
8
Analyses of U.S. FDA GCP Assessments and Recommendations for Marketing Applications, 2015–2024
2026
·
Courtney McGuire
, Michelle Foringer
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
Lessons and Insights from a Case Study on Clinical Trial Fraud
2026
·
Courtney McGuire
, Jenn W. Sellers
, et al.
·
Therapeutic Innovation & Regulatory Science
·
1
The Food and Drug Administration's Drug Safety Oversight Board: An Evolving Paradigm for Clinical Input on Drug Safety Topics
2010
·
C A Grandinetti
, S F Osborne
·
Clinical Pharmacology & Therapeutics
·
1
Supplementary Material for: Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010–2016: A Systematic Literature Review
2018
·
Perry, B.
, Herrington, W.
, et al.
·
Figshare
Show more works
View as search
Works count:
15
Citation count:
462
H-index:
9
I10-index:
9
Year
Topic
Type